Toyobo Co. Ltd. – FDA 483, Feb 22, 2023
An FDA inspection of Toyobo, Co., LTD in Otsu, Shiga, Japan, a sterile drug manufacturer, revealed significant deficiencies. The firm failed to adequately validate aseptic sterilization processes, establish proper production and process controls for light-sensitive APIs, and ensure scientifically sound laboratory testing for bacterial endotoxins. Additionally, procedures for preventing microbiological contamination were not followed, and complaint investigations lacked adherence to established quality information handling rules.
ID · 47f45e6d-261d-412b-b32a-c9dc42701ba7
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.